Market Context — Why This Technology, Why Now

The push for precision medicine and accelerated drug discovery demands increasingly sensitive and accurate analytical tools. This technology aligns with global trends towards miniaturized assays, high-throughput screening, and non-invasive diagnostics. By enabling clearer signals and higher sensitivity, it supports faster identification of promising drug candidates and more reliable diagnostic outcomes, driving competitive advantage in a rapidly evolving market.

Key Competitive Advantages
01

Enhances Detection Accuracy by up to 1.5x through Short-Wavelength Emission

02

Improves Detection Sensitivity by 20% with Superior Signal-to-Noise Ratio

03

Secures Long-Term Business Foundation with Strong IP Protection until 2041

Market Opportunity
Life Science Research Reagents
$4B globally (AI est.)
Demand for bioluminescence assays is increasing in basic research for gene expression analysis, protein interaction analysis, and cell activity measurement.
Research reagent manufacturers Academic research institutions Biotechnology companies developing assay kits
Drug Discovery Screening
$2.5B globally (AI est.)
There is a high need for sensitive and efficient detection systems in high-throughput screening, directly leading to shorter drug development times and reduced costs.
Large pharmaceutical companies Contract Research Organizations (CROs) Biotech firms specializing in drug discovery platforms
Clinical Diagnostics & IVD
$3.5B globally (AI est.)
Highly sensitive and specific biomarker detection technologies are required for early disease detection and treatment monitoring. Short-wavelength luminescence could reduce autofluorescence interference and enhance diagnostic accuracy.
In vitro diagnostic (IVD) manufacturers Medical device companies Diagnostic kit developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent broadly covers novel heterocyclic compounds and their salts, as well as luminescent substrate compositions utilizing them. It has successfully navigated prior art challenges and multiple office actions, indicating a robust and stable IP with low invalidation risk, providing a strong foundation for licensees.

Competitive White Space

This patent focuses on the compound structure and its use as a substrate. White space exists in developing novel detection devices or integrated assay platforms that leverage this short-wavelength emission, or exploring *in vivo* imaging applications.

Economic Impact
~$5.0M/year estimated R&D cost reduction per large pharmaceutical facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming a large pharmaceutical company conducts 100,000 high-throughput screenings (HTS) annually, with a re-screening cost of $1,000 per run. If this technology improves detection accuracy and reduces the re-screening rate by 5%, an annual cost reduction of $5,000,000 (AI est.) could be achieved (100,000 runs × 5% × $1,000).

Speed to Market
6× faster than in-house development
This technology involves novel heterocyclic compounds with established synthesis methods and evaluated luminescence properties. Licensees can significantly reduce the R&D period typically required for de novo compound design, synthesis, and characterization (usually over 3 years), potentially integrating and evaluating the compounds into existing bioluminescence assay systems within approximately six months. This enables early product launch and service deployment, establishing a competitive advantage.
Competitive Positioning

X: Luminescence Efficiency & S/N Ratio
Y: Autofluorescence Suppression Effect

Business Models & Applications
🧪 Reagent Kit Sales
Developing and directly selling bioluminescence assay kits, with this compound as a key component, to research institutions and pharmaceutical companies could secure a stable revenue stream.
🤝 Technology Licensing
Granting licenses to existing diagnostic or research reagent manufacturers could enable broad market expansion with reduced initial investment, while also securing royalty income.
🔬 Contract Analysis & Collaborative Research
Offering high-sensitivity bioassay services using this technology, or engaging in collaborative research for specific disease biomarker discovery, could create new insights and revenue opportunities.
Adjacent Application Opportunities
🧪 Environmental Monitoring
High-Sensitivity Pollutant Biosensors
By combining this technology with microbial biosensors, a system could be developed for highly sensitive detection of trace harmful substances or endocrine disruptors in water. Short-wavelength luminescence would avoid water autofluorescence, enabling clearer signals for early pollution detection.
🍎 Food & Agriculture
Food Freshness & Safety Assessment Systems
This technology could be applied to bioluminescence assays for rapid and highly sensitive detection of specific enzyme activities indicating bacterial contamination or spoilage in food products. This is expected to streamline food quality control processes and enhance food safety.
💊 Medical & Healthcare
Drug Efficacy Assessment for Personalized Medicine
Applying this technology to drug efficacy assays using patient-derived cells could enable highly sensitive detection of individual differences in drug response, supporting optimal treatment selection. Short-wavelength luminescence would contribute to high-precision information acquisition from low-invasive biological samples.
Integration Roadmap — Estimated 24-Month Deployment
Phase 1: Validation & Assay Optimization
Duration: 6 months
Validate the compatibility of this compound with the licensee's existing bioluminescence systems and identify optimal reaction conditions and concentrations. Acquire foundational data to demonstrate the superiority of short-wavelength luminescence.
Phase 2: Prototype Development & Evaluation
Duration: 9 months
Develop prototypes for specific applications (e.g., drug screening kits) based on the optimized assay protocol. Conduct internal performance evaluations and collaborative assessments with external partners.
Phase 3: Commercialization & Market Launch
Duration: 9 months
Incorporate prototype evaluation results, establish quality control for the product, and build manufacturing and sales systems. Initiate marketing activities for target markets and aim for product launch.
Technical Feasibility
This technology is a novel heterocyclic compound compatible with existing firefly bioluminescence systems, primarily introduced as a reagent. It does not require special hardware modifications or large-scale capital investment. The patent claims and detailed description clearly specify the compound's structure and synthesis pathway, allowing licensees to synthesize the compound and integrate it as a substrate into existing bioluminescence assay systems to quickly leverage the benefits of short-wavelength emission.
Success Scenario
Upon adopting this technology, drug discovery screening could detect target molecule activity with clearer signals and higher sensitivity. This is estimated to shorten the identification period for promising compound candidates by 20% compared to conventional screening processes, significantly reducing annual development costs. Furthermore, the development of new short-wavelength luminescence assays could offer unique diagnostic solutions not available to competitors.
Patent Record
APPLICATION NO.
特願2021-032167
REGISTRATION NO.
7713216
FILING DATE
2021/03/01
GRANT DATE
2025/07/16
EXPIRATION DATE
2041/03/01
PATENT HOLDER
国立大学法人電気通信大学
Examination History
2024年01月25日
出願審査請求書
2024年12月17日
拒絶理由通知書
2025年02月13日
意見書
2025年02月13日
手続補正書（自発・内容）
2025年04月22日
拒絶理由通知書
2025年06月20日
意見書
2025年06月20日
手続補正書（自発・内容）
2025年07月01日
特許査定